Bavituximab plus pembrolizumab combination achieved a 62.5% response rate in biomarker positive subgroup of hepatocellular cancer patients Data reinforce the potential of Xerna TME Panel to substantially improve outcomes for patients…
A MedUni Vienna research team has discovered a highly potent biomarker for clinical response to CAR-T cell therapy, describing the prerequisites for optimal use of this novel therapy for lymphoma treatment. The current findings are an…
RVT-3101 demonstrated statistically significant and clinically meaningful efficacy at each dose testedAcross all patients treated with RVT-3101, the clinical remission and endoscopic improvement rates were 32% and 40%, respectively.…
A group of neuroscientists led by a University of Pittsburgh School of Medicine researcher developed a test to detect a novel marker of Alzheimer's disease neurodegeneration in a blood sample. A study on their results was published today in…
Updated Results from CHARIOT Phase 2 trial presented at the 2022 ASH Annual Meeting indicate a 73.3% overall response rate and 60% complete response rate from 15 heavily pre-treated patients dosed with TT11 Research presented in an oral…
New York, USA, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Vocal Biomarkers Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), “Vocal Biomarkers Market Information By Type, Indications, End User,…